

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 5 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 10 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) and Figure 124 (SEQ ID NO:423).

20

2. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:11), Figure 8 (SEQ ID NO:17), Figure 10 (SEQ ID NO:22), Figure 12 (SEQ ID NO:27), Figure 14 (SEQ ID NO:33), Figure 16 (SEQ ID NO:38), Figure 18 (SEQ ID NO:48), Figure 21 (SEQ ID NO:58), Figure 23 (SEQ ID NO:63), Figure 25 (SEQ ID NO:68), Figure 27 (SEQ ID NO:70), Figure 29 (SEQ ID NO:72), Figure 31 (SEQ ID NO:83), Figure 33 (SEQ ID NO:90), Figure 35 (SEQ ID NO:95), Figure 37 (SEQ ID NO:103), Figure 39 (SEQ ID NO:108), Figure 41 (SEQ ID NO:113), Figure 43 (SEQ ID NO:118), Figure 45 (SEQ ID NO:126), Figure 47 (SEQ ID NO:131), Figure 49 (SEQ ID NO:136), Figure 51 (SEQ ID NO:141), Figure 53 (SEQ ID NO:147), Figure 55 (SEQ ID NO:152), Figure 57 (SEQ ID NO:158), Figure 59 (SEQ ID NO:163), Figure 61 (SEQ ID NO:169), Figure 63 (SEQ ID NO:174), Figure 65 (SEQ ID NO:176), Figure 67 (SEQ ID NO:184), Figure 69 (SEQ ID NO:189), Figure 71 (SEQ ID NO:194), Figure 73 (SEQ ID NO:200), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:212), Figure 79 (SEQ ID NO:220), Figure 81 (SEQ ID NO:226), Figure 83 (SEQ ID NO:235), Figure 85 (SEQ ID NO:244), Figure 87 (SEQ ID NO:249), Figure 89 (SEQ ID NO:254), Figure 91 (SEQ ID NO:256), Figure 93 (SEQ ID NO:258), Figure 95 (SEQ ID NO:260), Figure 97 (SEQ ID NO:262), Figure 99 (SEQ ID NO:284), Figure 101 (SEQ ID NO:289), Figure 103 (SEQ ID NO:291), Figure 105 (SEQ ID NO:293), Figure 107 (SEQ ID NO:309), Figure 109 (SEQ ID NO:314), Figure 111 (SEQ ID NO:319), Figure 113 (SEQ ID NO:324), Figure 115 (SEQ ID NO:331), Figure 117 (SEQ ID NO:338), Figure 119 (SEQ ID NO:340), Figure 121 (SEQ ID NO:376) and Figure 123 (SEQ ID

NO:422), or the complement thereof.

3. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the full-length coding sequence of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:11), Figure 8 (SEQ ID NO:17), Figure 10 (SEQ ID NO:22), Figure 12 (SEQ ID NO:27), Figure 14 (SEQ ID NO:33), Figure 16 (SEQ ID NO:38), Figure 18 (SEQ ID NO:48), Figure 21 (SEQ ID NO:58), Figure 23 (SEQ ID NO:63), Figure 25 (SEQ ID NO:68), Figure 27 (SEQ ID NO:70), Figure 29 (SEQ ID NO:72), Figure 31 (SEQ ID NO:83), Figure 33 (SEQ ID NO:90), Figure 35 (SEQ ID NO:95), Figure 37 (SEQ ID NO:103), Figure 39 (SEQ ID NO:108), Figure 41 (SEQ ID NO:113), Figure 43 (SEQ ID NO:118), Figure 45 (SEQ ID NO:126), Figure 47 (SEQ ID NO:131), Figure 49 (SEQ ID NO:136), Figure 51 (SEQ ID NO:141), Figure 53 (SEQ ID NO:147), Figure 55 (SEQ ID NO:152), Figure 57 (SEQ ID NO:158), Figure 59 (SEQ ID NO:163), Figure 61 (SEQ ID NO:169), Figure 63 (SEQ ID NO:174), Figure 65 (SEQ ID NO:176), Figure 67 (SEQ ID NO:184), Figure 69 (SEQ ID NO:189), Figure 71 (SEQ ID NO:194), Figure 73 (SEQ ID NO:200), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:212), Figure 79 (SEQ ID NO:220), Figure 81 (SEQ ID NO:226), Figure 83 (SEQ ID NO:235), Figure 85 (SEQ ID NO:244), Figure 87 (SEQ ID NO:249), Figure 89 (SEQ ID NO:254), Figure 91 (SEQ ID NO:256), Figure 93 (SEQ ID NO:258), Figure 95 (SEQ ID NO:260), Figure 97 (SEQ ID NO:262), Figure 99 (SEQ ID NO:284), Figure 101 (SEQ ID NO:289), Figure 103 (SEQ ID NO:291), Figure 105 (SEQ ID NO:293), Figure 107 (SEQ ID NO:309), Figure 109 (SEQ ID NO:314), Figure 111 (SEQ ID NO:319), Figure 113 (SEQ ID NO:324), Figure 115 (SEQ ID NO:331), Figure 117 (SEQ ID NO:338), Figure 119 (SEQ ID NO:340), Figure 121 (SEQ ID NO:376) and Figure 123 (SEQ ID NO:422), or the complement thereof.

4. Isolated nucleic acid which comprises the full-length coding sequence of the DNA deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400, ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403, ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489, ATCC 209433, ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484, ATCC 209371 or ATCC 203553.

5. A vector comprising the nucleic acid of Claim 1.

35 6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7 wherein said cell is a CHO cell.

9. The host cell of Claim 7 wherein said cell is an *E. coli*.

10. The host cell of Claim 7 wherein said cell is a yeast cell.

5

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

10

12. Isolated native sequence PRO polypeptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) and Figure 124 (SEQ ID NO:423).

25

30 13. Isolated PRO polypeptide having at least 80% sequence identity to the amino acid sequence encoded by the nucleotide deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400, ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, 35 ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403, ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489,

ATCC 209433, ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484, ATCC 209371 or ATCC 203553.

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

5

15. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is an epitope tag sequence.

16. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is a Fc 10 region of an immunoglobulin.

17. An antibody which specifically binds to a PRO polypeptide according to Claim 12.

18. The antibody of Claim 17 wherein said antibody is a monoclonal antibody.

19. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), lacking its associated signal peptide;
(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69),

Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), lacking its associated signal peptide.

20. An isolated polypeptide having at least 80% amino acid sequence identity to:

35 (a) the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73),

Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), lacking its associated signal peptide;

(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), with its associated signal peptide; or

(c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID

NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221),
5 Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290),
10 Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332),
Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341), Figure 122 (SEQ ID NO:377) or Figure 124 (SEQ ID NO:423), lacking its associated signal peptide.

21. A method of detecting a PRO245 polypeptide in a sample suspected of containing a PRO245 polypeptide, said method comprising contacting said sample with a PRO1868 polypeptide and determining the formation of a PRO245/PRO1868 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO245 polypeptide in said sample.

22. The method according to Claim 21, wherein said sample comprises cells suspected of expressing said PRO245 polypeptide.

23. The method according to Claim 21, wherein said PRO1868 polypeptide is labeled with a detectable label.

24. The method according to Claim 21, wherein said PRO1868 polypeptide is attached to a solid support.

25. A method of detecting a PRO1868 polypeptide in a sample suspected of containing a PRO1868 polypeptide, said method comprising contacting said sample with a PRO245 polypeptide and determining the formation of a PRO245/PRO1868 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1868 polypeptide in said sample.

26. The method according to Claim 25, wherein said sample comprises cells suspected of expressing said PRO1868 polypeptide.

27. The method according to Claim 25, wherein said PRO245 polypeptide is labeled with a detectable label.

28. The method according to Claim 25, wherein said PRO245 polypeptide is attached to a solid

support.

29. A method of linking a bioactive molecule to a cell expressing a PRO245 polypeptide, said method comprising contacting said cell with a PRO1868 polypeptide that is bound to said bioactive molecule and allowing said PRO245 and PRO1868 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

30. The method according to Claim 29, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

10 31. The method according to Claim 29, wherein said bioactive molecule causes the death of said cell.

15 32. A method of linking a bioactive molecule to a cell expressing a PRO1868 polypeptide, said method comprising contacting said cell with a PRO245 polypeptide that is bound to said bioactive molecule and allowing said PRO245 and PRO1868 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

20 33. The method according to Claim 32, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

34. The method according to Claim 32, wherein said bioactive molecule causes the death of said cell.

25 35. A method of modulating at least one biological activity of a cell expressing a PRO245 polypeptide, said method comprising contacting said cell with a PRO1868 polypeptide or an anti-PRO245 antibody, whereby said PRO1868 polypeptide or said anti-PRO245 antibody binds to said PRO245 polypeptide, thereby modulating at least one biological activity of said cell.

30 36. The method according to Claim 35, wherein said cell is killed.

37. A method of modulating at least one biological activity of a cell expressing a PRO1868 polypeptide, said method comprising contacting said cell with a PRO245 polypeptide or an anti-PRO1868 antibody, whereby said PRO245 polypeptide or said anti-PRO1868 antibody binds to said PRO1868 polypeptide, thereby modulating at least one biological activity of said cell.

35 38. The method according to Claim 37, wherein said cell is killed.